title: Twenty-four weeks of interferon alpha-2b in combination with ribavirin for Japanese hepatitis C patients: sufficient treatment period for patients with genotype 2 but not for patients with genotype 1.
abstract: BACKGROUND
  Hepatitis C virus (HCV) RNA titer and HCV genotype are two major determinants of the outcome of interferon (IFN) monotherapy. To clarify the usefulness of combination therapy with IFN and ribavirin in Japanese hepatitis C patients, we treated patients with a relatively high dose of IFN in combination with ribavirin for 24 weeks and examined the effects in relation to the viral parameters.
  
  
  METHODS
  Two hundred and ninety-five patients were enrolled in the study. The patients received either 6 or 10 million units (MU) of interferon alpha-2b every day for 2 weeks and then three times a week for 22 weeks with a daily dose of either 600 or 800 mg of ribavirin. The treatment response and safety of this treatment were examined.
  
  
  RESULTS
  The sustained virologic response (SVR) rates were 26.8% in genotype 1 and 76.5% in genotype 2 (P < 0.001), and 36.1% with the 6 MU group and 45.8% with the 10 MU group (P = 0.09). Multivariate analysis indicated that SVR was associated with genotype 2, HCV RNA <500 kilointernational unit/ml (kIU/ml), and HCV RNA undetectability at week 8 of treatment.
  
  
  CONCLUSIONS
  Our current study showed that a 24-week course of IFN plus ribavirin combination therapy was effective with respect to virologic response in Japanese hepatitis C patients, particularly in patients with HCV genotype 2.
authors.affiliation: Department of Medicine and Clinical Oncology, Graduate School of Medicine, Chiba University, Chiba, Japan.
authors.forename: Keiichi
authors.initials: K
authors.lastname: Fujiwara
authors.forename: Osamu
authors.initials: O
authors.lastname: Yokosuka
authors.forename: Fumihiko
authors.initials: F
authors.lastname: Komine
authors.forename: Mitsuhiko
authors.initials: M
authors.lastname: Moriyama
authors.forename: Naoya
authors.initials: N
authors.lastname: Kato
authors.forename: Haruhiko
authors.initials: H
authors.lastname: Yoshida
authors.forename: Naohide
authors.initials: N
authors.lastname: Tanaka
authors.forename: Fumio
authors.initials: F
authors.lastname: Imazeki
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Shiratori
authors.forename: Yasuyuki
authors.initials: Y
authors.lastname: Arakawa
authors.forename: Masao
authors.initials: M
authors.lastname: Omata
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D004305:Dose-Response Relationship, Drug; D004359:Drug Therapy, Combination; D005260:Female; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000008:administration & dosage*; D007564:Japan; D008297:Male; D008875:Middle Aged; D015999:Multivariate Analysis; D012367:RNA, Viral / Q000097:blood; D011994:Recombinant Proteins; D012254:Ribavirin / Q000008:administration & dosage*; D016896:Treatment Outcome
chemical_list: D000077190:Interferon alpha-2; D016898:Interferon-alpha; D012367:RNA, Viral; D011994:Recombinant Proteins; D012254:Ribavirin